Evidence map›Paper›PMID 32865702›Full record

ArticleActa neurologica Belgica2021

The use of Modified Rio score for determining treatment failure in patients with multiple sclerosis: retrospective descriptive case series study.

Mesude Tutuncu, Ayse Altintas, Burcu V Dogan, Ugur Uygunoglu, Nilufer Kale Icen, Ayse Deniz Elmalı, Eda Coban, Bengi G Alpaslan, Aysun Soysal

Erratum issuedAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Acta neurologica Belgica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Predictive MRI Biomarkers in MS-A Critical Review.Medicina (Kaunas, Lithuania) · 2022
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Mesude TutuncuBakirkoy Prof. Dr. Mazhar Osman Training and Research Hospital for Psychiatry and Neurological Disorders, Zuhuratbaba Mah. Bakirkoy Ruh Sağlığı Ve Sinir Hastalıkları Hastanesi, bitam binasıi 3, Noroloji kliniği Bakirkoy, 34147, Istanbul, Turkey. mesudeozerden@yahoo.com.ORCID http://orcid.org/0000-0002-1176-3156
Ayse AltintasKoc University Medical School, Topkapı, Koç Üniversitesi Hastanesi, Davutpaşa Cd. No:4, 34010 Zeytinburnu/İstanbul, 34200, Istanbul, Turkey.
Burcu V DoganBakirkoy Prof. Dr. Mazhar Osman Training and Research Hospital for Psychiatry and Neurological Disorders, Zuhuratbaba Mah. Bakirkoy Ruh Sağlığı Ve Sinir Hastalıkları Hastanesi, bitam binasıi 3, Noroloji kliniği Bakirkoy, 34147, Istanbul, Turkey.
Ugur UygunogluCerrahpasa School of Medicine, Cerrahpasa mahallesi, Kocamustafapasa cad. No: 34/E Noroloji Klinigi Fatih, 34200, Istanbul, Turkey.
Nilufer Kale IcenBagcilar Research and Tarining Hospital, Merkezmah. Dr. Sadık Ahmet Cad. Bagcılar, 34100, Istanbul, Turkey.
Ayse Deniz ElmalıNeurology Department, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Eda CobanBakirkoy Prof. Dr. Mazhar Osman Training and Research Hospital for Psychiatry and Neurological Disorders, Zuhuratbaba Mah. Bakirkoy Ruh Sağlığı Ve Sinir Hastalıkları Hastanesi, bitam binasıi 3, Noroloji kliniği Bakirkoy, 34147, Istanbul, Turkey.
Bengi G AlpaslanCerrahpasa School of Medicine, Cerrahpasa mahallesi, Kocamustafapasa cad. No: 34/E Noroloji Klinigi Fatih, 34200, Istanbul, Turkey.
Aysun SoysalBakirkoy Prof. Dr. Mazhar Osman Training and Research Hospital for Psychiatry and Neurological Disorders, Zuhuratbaba Mah. Bakirkoy Ruh Sağlığı Ve Sinir Hastalıkları Hastanesi, bitam binasıi 3, Noroloji kliniği Bakirkoy, 34147, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Predicting treatment failure and switching effective treatment immediately in patients with multiple sclerosis (MS) is important. We aimed to evaluate the usefulness of Modified Rio score (MRS) in predicting treatment failure in MS patients. This is a retrospective study, which was conducted in two University Hospital. 129 MS patients treated with İnterferon or glatiramer-acetate from 2 clinical sites, were retrospectively selected. MRS was calculated after the first year of therapy. Treatment failure was defined as the presence of a 1 point increase in EDSS, 2 clinical attacks, 1 clinical attack and progression, 1 clinical attack and new lesion on MRI except associated with an attack, or new lesion in 2 different MRI taken at least 3 months apart. The sensitivity, specificity, positive and negative predictive values of the MRS in predicting treatment failure were determined. 71 (55%) patients with score '0', 41 (31.8%) patients with score '1', 11 (8.5%) patients with score '2', 6 (4.7%) patients with score '3' were detected. 14 patients needed treatment switching during the first three years of the treatment. Sensitivity was 57%, specificity was 92%, positive predictive value was 95%, negative predictive value was 47% and accuracy was 89%. Modified Rio score (MRS) was found to be effective in determining the treatment failure as mentioned before. This study will be useful for clinicians who evaluate the treatment failure like us, and this study revealed that the MRS may also help predict treatment failure.

Indexed as

Disease ProgressionTreatment FailureAdjuvants, ImmunologicAdolescentAdultFemaleGlatiramer AcetateHumansImmunosuppressive AgentsInterferon beta-1aMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingRetrospective StudiesYoung AdultAdjuvants, ImmunologicGlatiramer AcetateImmunosuppressive AgentsInterferon beta-1aDisabilityMultiple sclerosisTreatment response

Identifiers

PMID32865702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.